Adherence to antipsychotic medication: discontinued medication · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes adherence to antipsychotic medication: discontinued medication compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes adverse effects. 1. Movement disorders ‐ any extrapyramidal compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes leaving the study early ‒ any reason compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Mental state: 2. Specific‐ Positive symptoms, total score‐ average endpoint scores (SADS‐C‐PD scale, lower = better) · people with both severe mental illness and substance misuse
1 finding from 1 review
Substance use: 1. Reduction of cannabis use‐change data (number of joints smoked/week) · people with both severe mental illness and substance misuse
1 finding from 1 review
Self‐reported potency · post‐prostatectomy erectile dysfunction (short‐term)
It is very uncertain whether scheduled PDE5I changes self‐reported potency compared with on demand placebo or no treatment (very low certainty).
1 finding from 1 review
Self‐reported potency · post‐prostatectomy erectile dysfunction (short‐term)
It is very uncertain whether scheduled PDE5I changes self‐reported potency compared with on demand PDE5I (very low certainty).
1 finding from 1 review
Erectile function · post‐prostatectomy erectile dysfunction (short‐term)
It is very uncertain whether scheduled PDE5I changes erectile function compared with on demand PDE5I (very low certainty).
1 finding from 1 review
Serious adverse events · post‐prostatectomy erectile dysfunction (short‐term)
It is very uncertain whether scheduled PDE5I changes serious adverse events compared with on demand PDE5I (very low certainty).
1 finding from 1 review
Sexual quality of life ‐ not reported · post‐prostatectomy erectile dysfunction (short‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · post‐prostatectomy erectile dysfunction (short‐term)
Scheduled PDE5I showed no clear difference in treatment discontinuation compared with on demand PDE5I (low certainty).
1 finding from 1 review
International Index of Erectile Function ‐ not reported · post‐prostatectomy erectile dysfunction (short‐term)
1 finding from 1 review
Erectile function · post‐prostatectomy erectile dysfunction (short‐term)
It is very uncertain whether scheduled PDE5I changes erectile function compared with on demand placebo or no treatment (very low certainty).
1 finding from 1 review
Self‐reported potency · post‐prostatectomy erectile dysfunction (short‐term)
It is very uncertain whether scheduled PDE5I changes self‐reported potency compared with scheduled intraurethral prostaglandin E1 (very low certainty).
1 finding from 1 review
Erectile function · post‐prostatectomy erectile dysfunction (short‐term)
It is very uncertain whether scheduled PDE5I changes erectile function compared with scheduled intraurethral prostaglandin E1 (very low certainty).
2 findings from 1 review
Serious adverse events ‐ not reported · post‐prostatectomy erectile dysfunction (short‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sexual quality of life ‐ not reported · post‐prostatectomy erectile dysfunction (short‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · post‐prostatectomy erectile dysfunction (short‐term)
Scheduled PDE5I may leads to lower serious adverse events compared with on demand placebo or no treatment (low certainty).
1 finding from 1 review
Treatment discontinuation · post‐prostatectomy erectile dysfunction (short‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
International Index of Erectile Function ‐ not reported · post‐prostatectomy erectile dysfunction (short‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found